Related Experiment Video
Updated: Jul 15, 2025
Lipidomics and Transcriptomics in Neurological Diseases
Published on: March 18, 2022
Palmitoylethanolamide shows limited efficacy in controlling cerebral cryptococcosis in vivo
Melissa E Munzen1, Marta Reguera Gomez1, Mohamed F Hamed1,2
1Department of Oral Biology, University of Florida College of Dentistry , Gainesville, Florida, USA.
Abstract:
Cryptococcus neoformans (Cn) is an encapsulated neurotropic fungal pathogen and the causative agent of cryptococcal meningoencephalitis (CME) in humans. Recommended treatment for CME is Amphotericin B (AmpB) and 5-fluorocytosine (5-FC). Though effective, AmpB has displayed numerous adverse side effects due to its potency and nephrotoxicity, prompting investigation into alternative treatments. Palmitoylethanolamide (PEA) is an immunomodulatory compound capable of promoting neuroprotection and reducing inflammation. To investigate the efficacy of PEA as a therapeutic alternative for CME, we intracerebrally infected mice with Cn and treated them with PEA or AmpB alone or in combination. Our results demonstrate that PEA alone does not significantly prolong survival nor reduce fungal burden, but when combined with AmpB, PEA exerts an additive effect and promotes both survivability and fungal clearance. However, we compared this combination to traditional AmpB and 5-FC treatment in a survivability study and observed lower efficacy. Overall, our study revealed that PEA alone is not effective as an antifungal agent in the treatment of CME. Importantly, we describe the therapeutic capability of PEA in the context of Cn infection and show that its immunomodulatory properties may confer limited protection when combined with an effective fungicidal agent.
Insights
Palmitoylethanolamide (PEA) shows limited efficacy against Cryptococcus neoformans (Cn) meningoencephalitis alone. However, combining PEA with Amphotericin B (AmpB) improves survival and fungal clearance, though less than standard AmpB and 5-FC treatment.
Area of Science:
- Mycology
- Immunology
- Pharmacology
Background:
- Cryptococcus neoformans (Cn) causes cryptococcal meningoencephalitis (CME), a serious human fungal infection.
- Standard treatment involves Amphotericin B (AmpB) and 5-fluorocytosine (5-FC), but AmpB has significant toxicity.
- Palmitoylethanolamide (PEA) is an endogenous compound with known immunomodulatory and neuroprotective effects.
Purpose of the Study:
- To evaluate Palmitoylethanolamide (PEA) as a potential therapeutic agent for cryptococcal meningoencephalitis (CME).
- To assess the efficacy of PEA alone and in combination with Amphotericin B (AmpB) against Cn infection in a murine model.
Main Methods:
- Intracerebral infection of mice with Cryptococcus neoformans (Cn).
- Treatment groups included PEA alone, AmpB alone, and PEA combined with AmpB.
- Comparison of combination therapy efficacy against standard AmpB and 5-FC treatment.
Main Results:
- PEA monotherapy did not significantly improve survival or reduce fungal burden in mice with CME.
- Combination therapy with PEA and AmpB demonstrated an additive effect, enhancing survivability and fungal clearance compared to AmpB alone.
- The PEA and AmpB combination showed lower efficacy than the standard AmpB and 5-FC treatment regimen.
Conclusions:
- Palmitoylethanolamide (PEA) is not effective as a standalone treatment for cryptococcal meningoencephalitis (CME).
- PEA's immunomodulatory properties may offer limited synergistic protection when combined with potent antifungal agents like AmpB.
- Further research is needed to explore PEA's role in managing Cn infections, potentially as an adjunct therapy.
